Centrilobular necrosis and a ten-fold elevation in serum alanine amino-transferase (ALT) consistently followed 2 hours of 1 % halothane anaesthesia in an animal model. Conditional factors were the presence oj enzyme induction and moderate hypoxia (14 % oxygen), indicating an association between reductive metabolism and hepatotoxicity. Under these conditions there was at least a jour-jold increase in reductive metabolites detected in the exhaled air.
INTRODUCTION
Throughout initial investigations of the pharmacology of halothane (Raventos 1956) and in the early years of its use no evidence of a direct hepatotoxicity of this drug was demonstrated (Virtue et al. 1958) . Clinical reports of massive hepatic necrosis following halothane anaesthesia began to appear in the literature, but there was no conclusive evidence of any potential hepatotoxicity (Bunker and Blumenfeld 1963) . Unfortunately many clinical reports of "halothane hepatitis" ignored alternative causes of postoperative jaundice such as proven hepatotoxic drugs (e.g. phenelzine, antibiotics or tranquillizers), shock, transfusion, hyperpyrexia, bacterial sepsis and viral infection. Although claims were made of a "typical" lesion of halothane hepatotoxicity (Trey et al. 1968 ), observer bias was not eliminated by these authors. Because of these difficulties some authors concluded quite properly that the association between halothane anaesthesia and hepatotoxicity was equivocal ( Simpson et al. 1974) . The "National Halothane Study" (1969) , a large retrospective investigation, failed to demonstrate a direct relationship between halothane and hepatotoxicity. However, a useful finding from this study was that if halothane was capable of causing hepatic necrosis in man then the incidence was probably less than 1 in 10,000. In a recent "case study" of 203 cases of Anaesthesia and Intensive Care, Vol. Vll, No. 1, February, 1979 jaundice after halothane 76 were unexplained and 95 % of these followed multiple exposures (Walton et al. 1976) . Some felt that this pointed to an "allergic" mechanism, although several studies have not revealed the hallmarks of allergic reactions and in particular, the lymphocyte transformation test is unaffected by halothane (Walton et al. ] 973). Others postulated that halothane anaesthesia may increase the likelihood of hepatic necrosis in patients incubating viral hepatitis at the time of anaesthetic administration. However experience in anaesthetizing patients with chronic liver disease who are carriers of HB,Ag suggests that activation of the virus does not follow uneventful anaesthesia and surgery (Dykes 1977) .
Because of the apparent rarity of hepatic necrosis after halothane anaesthesia, any remaining possible mechanism would have to invoke either an IDIOSYNCRATIC (probably PHARMACOGENETIC) reaction or have a MULTIFACTORIAL basis. Brown and Sipes ( 1977) noted in a review that in the presence of enzyme induction with phenobarbitone, halothane administered with 14% oxygen caused centrilobular necrosis in rats. To date there has been no evidence that data from this model could be extrapolated to man since no attempt had been made to match the rate and route of halothane metabolism in the model and man. The recent description of both oxidative and reductive halothane metabolites in man by Cohen's group has helped to define a possible mechanism for metabolite induced hepatotoxicity: Cohen et al. (1975) reported the presence of reductive N-acetyl cysteine and ox'dative ethanolamide conjugates, which cle?r1y indicated binding of met<:,bolites to cellu 12r ~()nstituents. I n a later study (Sharp et al. 1978) . direct evidence was present~d that halothane is metabolized in man by an alternative reductive path to some extent even at normoxia, indicating the formation of small amounts of reactive intermediates.
In considering potential animal models for halothane metabolism and hepatotoxicity, previous data were examined in relation to metabolism of halogenated hydrocarbon anae<;thetics and organ susceptibility to toxic metabolites. It apoears that some species (e.g. the dog) metabolise halogenated anaesthetics at a relatively slow rate and that organ sensitivity to toxic metabolites tends to be low (Frascino et al. 1972) . Furthermore, it is now known that there are strain differences among rats in the biotransformation of these drugs and organ sensitivity to toxic metabolites . A series of studies in rats has indicated that one particular strain, the Fischer 344 rat, metabolized at least three halogenated anaesthetics, methoxyflurane, cnflurane and isoflurane, similarly to man , Barr et al. 1974 , Cousins et al. 1976 .
I n the first four studies both the metabolism and organ sensitivity to toxic metabolites were very similar to man. Thus this rat strain appeared promising as a model of halothane metabolism. However, in the last study of isoflurane although the major metabolites were the same, their proportions were different, with the amounts of organic metabolite much higher in man. Also, other investigators have shown that the organic metabolites of at least one agent, f1uoroxene, were quite different in man compared to several animal species (Johnston et al. 1973) . It was therefore important to document the major oxidative and reductive metabolites of halothane in this proposed model and to make comparisons with man.
The aim of this study was to determine if halothane's oxidative and reductive metabolism was similar in a model and man. The model was also employed to determine if functional and morphological chan~es occurred consistently when halothane metabolism was quantitatively chaneed by enzyme induction, and reductive metabolism was increased by the presence of moderate hypoxia.
METHODS

I. ANIMAL STUDIES (a) Halothane metabolism and hepatotoxicit)': effect of enzyme induction and hypoxia.
Three-month-old inbred male Fischer 344 rats of weight 220-280 g were housed since birth in common cages of 5 animals per cage. Thev were bedded on sawdust which does not rp<;ult in pnzymp induction and received Charlicks M&V cubes and tap water ad libitum. White fluorescent light was present 7 a.m. to 7 n.m. daily, and room temperature was rnqintained at 24 ne. Animals were randomly allocated so that half of the animals received tan water. and the remainder received 0.15% sodinm ohenobarbitone in their drinking water, for 7 days. Animals were weighed daily. At th~ end (If the period the animals were randomly allocated to one of six treatment groups. Animals from Group I and Group IVroom air for 2 hours These animals were placed in a common chamber for the 2 hours duration of treatment in the other groups, and breathed room air.
Animals from Group II and Group V -14% oxygen, 86% nitrogen for 2 hours These animals were placed in a common chamber with control of temperature and inspired oxygen concentration. Oxygen concentration was held at 14% for 2 hours aided by a continuous recording mass spectrometer. Other management was as described below.
Animals from Group III and Group VI 14% oxygen, 85% nitrogen and 1 % halothane for 2 hours Animals were placed in a common chamber with temperature control by means of an electric blanket under the floor of the chamber, and a rectal telethermometer probe for each animal. Halothane 2 % with 98 % oxygen was admitted to the chamber at a flow rate of 6 l/minute from a previously calibrated Fluotec Mk III vaporizer until the animals were anaesthetized (5 minutes). Their heads were then individually moved into a multi port glass rat mask assembly ( Figure 1 ). Each port accommodated a rat head up to ~he level of the ears, and made a seal round the head with surgical latex rubber, without obstructing respiration. The six entry ports were connected to a central glass chamber containing soda • It had previously been determined that there were no significant elev~tions in ser~m ALT following halothane in 21 % oxygen wIth phenobarbItone pretreatment and reductive metabolite levels were similar to those observed after halothane alone in 100% oxygen. lime to absorb CO 2 , The assembly was designed to provide non-rebreathing at each animal port since the gas flow (2 l/min) entered above each animal's head and was directed past the animal's nostrils to the chamber, and then to a centrally placed exit tube ( Figure 1 ). All fittings and piping between the vaporizer and mask assembly were either copper or stainless steel. FG FIGURE l.-Multiport rat mask assembly. Each port (P) accommodates a rat head to the level of the ears and makes a seal with a latex rubber diaphragm. The six ports are connected to a central glass chamber (C) containing soda lime. The fresh gas supply (FG) enters above each animal head. The central exit tube (E) is used to vent excess gas and also for gas sampling. The sixth port is used for insertion of a mass spectrometer probe for continuous measurement of gaseous concentrations of halothane, oxygen and carbon dioxide.
Oxygen concentration in the mask was continuously monitored by a mass spectrometer (Centronix 200 MGA) via a probe introduced th~ough a port of the glass assembly and adjusted to ± 0.5% of 14%. Carbon dioxide and halothane concentration in the mask were similarly monitored. Halothane concentration was adjus~ed to 1 ± 0.05 %. Mean expired concentratIOns of oxygen, carbon dioxide and h~lothane were measured continuously; at 15 mInute intervals inspired-expired concentrations were measured by placing the mass spectrometer probe in a rat nostril. Arterialized tail blood samples (100 ",I) were collected half hourly for measurement of PO:!, PCO:!, pH (IL213 blood gas analyzer), and blood anaesthetic ~o.nce.ntra~ion (gas chromatography, by direct injectIOn Into a Varian 1440 gas chromatograph). In a separate set of experiments tail blood gases were checked against femoral artery blood gases, obtained from femoral artery cannulae; direct blood pressure recordings were also made in these animals.
Anaesthesia and Intensive Care, Vol. VII, No. I, Februar) ', 1979 After 1 hour of anaesthesia *, gas samples were obtained from the central chamber by connecting a 20 ml ground glass syringe to the outlet tube, and aspirating 20 ml at the rate of 1 ml/second. During this sampling, and for 1 minute previously, the fresh gas flow was reduced to 13 ml/minute. Pilot studies indicated that this procedure permitted the most effective collection of alveolar gas and maintained the oxygen concentration in the chamber at essentially the same level as prior to sampling. The syringe contents were immediately analyzed as described below (gas chromatography analysis of volatile metabolites) .
At the end of 2 hours all animals were allowed to breathe room air, and returned to their cages when awake. Food and tap water were allowed ad libitum. All animals were sacrificed twenty-four hours later by stunning and decapitation. Approximately 3 ml of blood was collected from each animal, allowed to clot, centrifuged and serum immediately frozen for SGPT (ALT) analyses.
Morphological Studies
Samples of liver and kidney were obtained for light and electron microscopy. Liver tissue for the morphological studies was removed with a biopsy needle from the right lobe within 1 minute of decapitation. Two cores per animal were fixed in 2.5 % glutaraldehyde in 0.1 M sodium cacodylate buffer for 2 hours at room temperature. One core was processed intact, the other cut into 2 millimetre cubes. The cubes were post-fixed for 30 minutes in 1 % osmium tetroxide. All the material was then dehydrated in graded aIcohols and propylene oxide and embedded in araldite.
Whole cores were sectioned at 2 microns on an L.K.B. paramitome. Sections were treated with saturated sodium hydroxide in alcohol to remove resin and stained with ei~her haematoxylin and eosin or periodic-acid Schiff for light microscopic examination.
The cubes were sectioned for electron microscopy on an L.K.B. ultratome III or a Reichert F.C.2. One micron sections were stained with toluidine blue for light microscopy assessment and ultrathin (gold) sections were stained with uranyl acetate and lead citrate for the electron microscope (Philips 201 C) study.
* Preliminary experiments showed that metabolit~ levels have reached a plateau after I hour.
(b) Reductive halothane metabolism in the absence of enzyme induction and hypoxia. Ten 3-month-old inbred male Fischer 344 rats had the same pre-anaesthetic regimen for 7 days as described above, but none were treated with phenobarbitone. On day 8 animals were placed in the common anaesthesia chamber 5 at a time until anaesthetized and then inserted in the glass mask assembly and managed as described above. However in these expenments, halothane 1 % with 99 % oxygen was administered to the first group of 5 and with 2 I % oxygen to the second group, at a flow rate of 2 I/minute. Analysis of reductive halothane metabolites was carried out as described below (gas chromatography analysis of volatile metabolites) .
In order to obtain a sample of normal volatile compounds in breath a further five animals were given hexobarbitone 125 mg/kg intraperitoneal, and then inserted into the mask assembly as noted above. Gas samples were obtained, while the animals breathed room air, and analyzed as described below.
H. HUMAN STUDIES
Volatile metabolites of halothane in the absence of hypoxia. Three patients, ASA Status I, scheduled for elective surgery were asked to participate in this study. Their anaesthetic management consisted of premedication with papaveretum 20 mg and scopolamine 0.4 mg per 70 kg. Induction was carried out with a sleep dose of thiopentone 2.5 % and tracheal intubation was facilitated by administration of 1 mg/kg of suxamethonium. The patient was then connected to a semi-closed circle absorption system with fresh soda lime and unused rubber connections. The circuit had been shown by gas chromatography to be free of anaesthetic. Muscle relaxation was maintained using 1 mg pancuronium per 10 kg. Ventilation was controlled to ensure that PaC0 2 remained close to 40 mm/Hg. A gas sampling catheter was placed so that its tip lay at the distal end of the cndotracheal tube. A gas sample for analysis of normal breath components was obtained. The probe of the mass spectrometer was then connected to this catheter to provide a continuous recording of inspired and end alveolar oxygen and halothane concentration in a similar manner to that described in Anaesthesia and Tntensive Care. Vol. Vll. No. 1, FeIJruarJ', 1979 experiment 1. Anaesthesia was then maintained by employing 1 % halothane, from a previously calibrated Fluotec Mk III vaporizer, in 5 l/min oxygen. Halothane dose was precisely 2 MAC hours .
Arterial blood samples were obtained for measurement of Pa02, PaC0 2 and pH. One hour after the start of anaesthesia fresh gas flow rate was reduced to 250 ml/min oxygen for 1 minute prior to and during gas sampling. Gas samples were then obtained in 20 ml ground glass syringes from the gas sampling catheter by aspirating at a rate of 50 ml/min. Samples were immediately analyzed as described below.
Gas chromatography analysis of volatile halothane metabolites
Gaseous samples from both animal and clinical studies were analyzed in the same manner. The contents of the 20 ml glass syringes were immediately injected into a stainless steel loop cooled in liquid nitrogen to permit condensation of the sample. Following condensation the contents of the loop were raised to room temperature, and injected via a 6 port gas sampling valve into a Hewlett Packard 5730A gas chromatograph with flame ionization detector and a carrier gas flow rate of 30 ml/min. The details of this analysis were as previously reported by Sharp et al. (1978) .
Peak areas for the volatile metabolites were related to the peak areas from a calibration curve of pure compounds. Supplies of pure compounds 2-chloro-l, I-difluoroethylene (CDF) and 2-chloro-l, 1, I-trifluoroe~hane (CTF) were obtained from PCR Research Chemicals Inc. * Retention times for these compounds were compared with those of peaks from both animal and human breath.
Identification of volatile metabolites
Gas samples were subjected to gas chromatography mass spectrometry performed on a Perkin Elmer gas chromatograph interfaced through a silicone membrane separator with an AEI MS 30 mass spectrometer. Mass spectra were measured at 70 eV with a source temperature of 150°C.
Non volatile halothane metabolites in animal model and man
Trifluoroacetic Acid Three Fischer 344 rats were placed in individual metabolic cages and 24 hour specimens of urine collected prior to and for • PCR Research Chemicals Inc., Gainesville, Fla. These compounds were shown to be greater than 99% pure by gas chromatography. 24 hours following 1 % halothane with 99% oxygen administered for 6 hours. Blood samples were collected for 2 days prior to and for 2 days post anaesthesia.
Twenty-four hour urine specimens were also collected from four patients prior to and for 24 hours following 1 MAC halothane (end alveolar concentration 0.7-0.8%) administered for 0.75 hours, 1.0, 1.8 and 2.5 hours respectively i.e. doses of 0.75 to 2.5 MAC hours. Blood samples were collected as above. Trifluoroacetic acid (TF A) analysis was carried out on a J eol JNM PS-lOO nuclear magnetic resonance (NMR) spectrometer using a fluorine (F) probe and fast fourier transform analysis, which allows rapid scanning and also accumulation of scans to improve the signal to noise ratio. TFA as trifluoroacetic acid gives a single F peak on NMR; the three F atoms being equivalent in the molecule. Using 0.5 ml of urine with trifluoroethanol added as an internal standard, TF A could be determined down to lO-4M (0.1 mM) after 2,000 x 3 second scans. This proved to be a rapid method for direct determination of TFA in urine.
Inorganic fluoride and inorganic bromide
Six Fischer 344 rats were studied. Serum samples were collected for 2 days prior to, at six hours post anaesthesia, and for 3 days following anaesthesia. On the day of anaesthesia 1 % halothane with 99 % oxygen was administered for 2 hours.
Three patients ASA I had serum samples collected as above. They received 1 % halothane with 99% oxygen for 2 hours on the operative day.
Inorganic fluoride concentration in urine and serum was measured by an ORlON ion selective electrode. Inorganic bromide concentration was measured only in the serum by a modification of the method of Poser (1974) : chloride interference was eliminated by matching the chloride concentration of sample and standard and cysteine interference was eliminated by a 1: 1 dilution with 0.1 M nitric acid.
RESULTS
I. ANIMAL STUDIES OF HALOTHANE HEPATOTOXICITY:
Enzyme induction, hypoxia and halothane. Animals maintained body temperature between 36 and 37°C, Blood gases in animals receiving 14% oxygen without anaesthesia (Group IJ and V) were: Pa02 59.8 ± 1.5 mmHg; PaC0 2 36.2 ± 1.3 mmHg; pH 7.54 FIGURE 3.-Light microscopy. PAS stain. TOP: Liver from control animals (Group I). Note: Normal "plate" pattern of liver cells and plentiful glycogen (purple). PAS stain x 400. BOTTOM: In comparison liver is shown from animals who received phenobarbitone, halothane and 14% oxygen (GROUP VI). Note loss of glycogen in centrilobular areas with confluence between neighbouring lobules. PAS stain x 100.
Anaeslhe.,;a alld Inlells;)'e Care, Vol. VII, No, I, February, 1979 ± 0.05. Blood gases in animals receiving 14% oxygen and 1 % halot:hane (Group III and Group VI) were: Pa02 47.4 ± 1.1 mmHg; PaC0 2 37.3 ± 1.9 mmHg; pH 7.48 ± 0.03. Blood pressure remained within 10% of pre-anaesthetic levels. All animals regained consciousness within 5 minutes of normoxic anaesthesia or within 10-15 minutes after hypoxic anaesthesia; all then resumed normal feeding and drinking.
Biochemical Determinations
Serum ALT was markedly increased in animals from Group VI (phenobarbitone, hypoxia and halothane). In all other groups serum AL T was similar to control levels ( Figure   2 ). Abbreviations: ALT = SERUM ALANINE AMINO TRANSFERASE (International Units), mean ± SD C(AIR) = GROUP I, control, no treatment through-out· P IB (AIR) = GROUP IV, phenobarbitone for 7 days alone; C(1 % HAL, 14% O2) = GROUP Ill, no treatment for 7 days followed by 14% oxygen and 1 % halothane for 2 hours on day 8; PIB (1% HAL, 14% O2) = GROUP VI, phenobarbitone for 7 days followed by same treatment as Group III on day 8; C(14% 02) = GROUP 11, no treatment for 7 days followed by 14% oxygen for 2 hours on day 8; PIB (14% 0,) = GROUP V, phenobarbitone for 7 days followed by same treatment as Group 11 on day 8.
Animals receiving phenobarbitone prior to halothane in an hypoxic oxygen mixture (14%) Group VI, had highly significant elevations in serum AL T (P < 0.001). Numbers in parenthesis represent the number of animals in each group.
Morphological Studies 1. Light Microscopy.
Liver sections from animals in Groups I-V showed no evidence of cellular damage. In contrast, sections from all animals in Group VI showed centrilobular glycogen depletion which was sometimes confluent. In these areas there was cell swelling and cytoplasmic pallor and increased fat. Some cells were grossly vacuolated and others showed eosinophilic necrosis with the formation of residual bodies. Nuclear changes also indicative of lethal cell injury included karyolysis and pyknosis. A slight mixed lymphocyte and polymorph infiltrate was present at the margin of and within the damaged areas. (Figures 3  and 4 
.)
In Group IV and V the only abnormality was an increase in fat which took the form of a generalized cytoplasmic vacuolation. 2. Electron Microscopy.
In Groups IV, V and VI there was an increase in hepatocyte lipid droplets and smooth endoplasmic reticulum resembling the changes usually described in phenobarbitone treated rats. In Group VI, some cells of the centrilobular zones of all animals showed the additional changes of severe cell injury. These included conspicuous swelling of the rough endoplasmic reticulum and nuclear changes including chromatin margination and sometimes swollen nuclear envelope ( Figure 5 ). Mitochondria showed variation in size: some were swollen while others were shrunken and distorted. A detailed hepatic morphological examination including quantitation will be the subject of a separate paper. Kidney sections from Group I-Vas well as Group VI animals showed no evidence of structural damage.
n. ANIMAL AND HUMAN STUDIES OF HALOTHANE METABOLISM:
Volatile metabolites of halothane
Analysis of gas samples from all animals receiving halothane revealed gas chromatographic peaks, peak A and peak B, wibh retention times of 1.54 and 3.36 minutes respectively. Comparison with pure compounds showed almost identical retention times for the compounds CDF and CTF, 1.55 and 3.34 minutes respectively ( Figure 6 ). Subsequent GC-MS of rat breath during halothane anaesthesia confirmed that peaks A and B present at the retention times noted above were CDF and CTF respectively (Table 1) . Note normal cigar shaped mitochondria with regular cristae pattern. Appearance and prevalence of rough and smooth endoplasmic reticulum is normal for the absence of enzyme induction. Only small amounts of lipid are seen.
ABOVE RIGHT (Group VI) (x 6,600)
Note shrunken mitochondria with disrupted cristae pattern. Rough endoplasmic reticulum is grossly swollen and smooth endoplasmic reticulum is clumped together. There is a considerable increase in the amount of lipid present. The nucleus is swollen and shows chromatin margination as well as swelling of the nuclear envelope. A. 20 ml injection (via GSV) of pure compounds CDF and CTF (lOO iLl of each gas in 2 litres N,) results in peaks at retention times 1.55 and 3.34 minutes respectively (Range 10). B. Injection of 20 ml breath sample from man (via GSV) following halothane anaesthesia with 100% oxygen. (Range 10.) Peaks are present at 1.53 and 3.34 minutes at the same retention times of the pure compounds CDF and CTF. The peak at 2.58 minutes was a mixture of BCDF and normal breath components. C. Injection of breath sample (20 mls) from animal model. following halothane anaesthesia with 100% oxygen (Range 100). As in man, peaks are present at 1.54 and 3.36 minutes respectively. Subsequent GC-MS analysis confirmed that these peaks represent CDF and CTF respectively (see Table 1 ). D. Injection of breath sample from man, following halothane (0.5 %) anaesthesia with 30% oxygen, 70% nitrous oxide (Range 10). Note the movement of both the CDF and CTF peaks to 1.41 and 3.01 minutes respectively because of the influence of the condensed nitrous oxide in the sample loop of the GSV. The CTF peak is present at 3.01 minutes and the BCDF peak at 2.35 minutes. Note: In all samples (B)-(D) the large peak at approximately 8 minutes is halothane. The peak at 0.81 is an injection peak. The additional small peak at a retention time of approximately six minutes has been traced to an impurity in the cylinder nitrogen used in the trapping procedure. The other peaks have not been identified.
Analysis of gas samples from man during halothane anaesthesia revealed similar GC peaks to those above (RT 1.53 and 3.34 minutes). Sharp et al. (1978) have previously confirmed by GC-MS that ~he compounds of RT 1.53 and 3.34 minutes are CDF and CTF respectively.
The peak at 2.5S minutes in the gas samples from man was previously identified as a mixture of 2-bromo-2 chloro-l, l-difluoroethylene (BCDF) by comparing with normal breath components and by preparation of BCDF in vitro: reaction of halothane and soda lime at 50 G C in vitro, in our studies, resulted in a peak at an identical retention time to BCDF. The small peaks between CTF and halothane in gas samples from both rats and man are artefactual, and are due to impurities in the cylinder nitrogen used II1 the trapping procedure.
In the absence of hypoxia the amounts of CTF and CDF in rats were small and the ratio of CTF jCDF was similar after halothane anaesthesia with 100 % oxygen (8: 1) or 21 % oxygen (7: 1) ( Table 2) . Following halothane anaesthesia with 100 % oxygen in man, at similar doses to the animal studies, the amount of CDF (0.8 ppm) was similar to that measured in the model (0.6 ppm). The amount of CTF was somewhat lower than in the model. The ratio of CTF jCDF in man was 3: 1 compared to the ratio 8: 1 seen in animals.
In the model, in the presence of hypoxia and enzyme induction there was a fourfold increase in CTF and an eightfold increase in CDF, following halothane anaesthesia ( Table   2) . Time course studies (to be reported elsewhere) have indicated that the levels of the two reductive metabolites have reached a plateau by this time in both animals and man. The levels at each oxygen concentration are the mean value of two independent determinations employing five rats each time. (b) Rats were treated with phenobarbitone (as described in the methods) prior to exposure to 1 % halothane for 2 hours. 
Non volatile metabolites
Although the NMR technique was not sensitive enough for definitive quantitative analysis it was possible to detect TF A in the urine of rat and man. As indicated in the NMR peaks of Figure 7 the amounts are approximately the same. Approximately 0.7, 1.1, 1.5 and 2.5 mM TFA was detected at doses of 0.75, 1.0, 1.8 and 2.5 MAC hours in man and 4.4 mM TF A was detected at a dose of 6 MAC hours in the animal model. Peak serum inorganic fluoride concentrations were less than 2 I'M in man and the rat. Peak serum bromide concentrations were 1 mM in man and 2 mM in the rat.
DISCUSSION
Hepatotoxicity has been demonstrated after clinical doses of halothane in an animal model with similar biotransformation of halothane to man. CentriIobular necrosis and a tenfold elevation in serum ALT was present in all animals treated with phenobarbitone prior to halothane and 14 % oxygen (Figures 2-5 ). Under these conditions there was a four-to eightfold increase in reductive metabolites indicating an association between reductive metabolism and hepatotoxicity.
The volatile reductive metaboIites CTF and CDF (Figure 8) have not previously been reported in a model capable of developing hepatic necrosis following halothane anaesthesia. It is surprising that small amounts of these metabolites are present after halothane anaesthesia with 100% oxygen in both man and the model. At the present time no direct relationship has been proven between either one of the presently detected reductive metabolites and the hepatic necrosis demonstrated in the animal model. However, the conditional factor of enzyme induction confirms that biotransformation is involved in halothane hepatotoxicity. The requirement for mild hypoxia indicates that the toxic metabolite is produced by reductive rather than oxidative metabolism. Further evidence is provided by our finding that amounts of reductive metabolite increased four-to eightfold following enzyme induction and halothane anaesthesia with hypoxia and this was associated with hepatic necrosis and marked elevation of serum ALT (Figures 2-5 studies have shown insignificant changes in serum ALT, and levels of CTF jCDF similar to halothane alone in 100% oxygen when halothane is administered in 21 % oxygen following phenobarbitone (Cousins et al. unpublished data) . It is quite possible t:hat the reductive metabolites which we have identified are not hepatotoxic in themselves. In fact, it is likely that the causative agent is a free radical or carbanion intermediate (Figure 8) , which is highly bound to liver macromolecules, and thus is not detectable in exhaled air or urine.
Under normoxic conditions the reductive non-volatile metabolite inorganic (F-) was detected in human and rat serum at similar concentrations, and has been previously reported in both human and rat serum following halpthane anaesthesia (Mazze et al. 1972, Cousins and . The oxidative organic metabolite trifluoroacetic acid (TF A) was detected in both human and rat urine at similar concentrations.
The non-volatile metabolite inorganic bromide (Br) was detected in human and rat serum, also at similar concentrations. It is interesting that Br is formed by both oxidative and reductive routes of halothane biotransformation (Figure 8) .
It is clear from the foregoing that recent progress in understanding of halothane hepatotoxicity in man is due to advances in knowledge of HALOTHANE METABOLISM and DEVELOPMENT OF A MODEL FOR HALOTHANE HEPATOTOXICITY (the latter term is now more apt than "hepatitis"). The information relating to these two areas can now be conveniently summarized as follows:
HALOTHANE METABOLISM
The first metabolites of halothane to be identified, TF A and Br are products of an OXIDATIVE pathway as is TFA ethanolamide; BCDF is a reductive metabolite (Cohen et al. 1975) (Figure 8) . The latter were significant in that j1hey indicated possible binding of halothane metabolites to liver macromolecules. Widger et al. (1976) have subsequently reported the formation of free Fin the urine of rats following halothane anaesthesia and Van Dyke and have shown increased amounts of Fin the presence of severe hypoxia, in vitro.
More recently Mukai et al. (1977) reported two volatile reductive halothane metabolites CTF and CDF in the eX'haled air of rabbits, and these have been detected in our studies in man and also in the studies of Sharp et al. (1978) . The ratio of CTF and CDF reported by Mukai et al. (1977) following halothane in 100% oxygen was 10: 1 and in our studies in the animal model the ratio was 8: 1. This compares to a ratio of 3: 1 in man. Since the amount of CDF was almost identical in our studies in man to that in the model and the amount of CTF was similar, this provides strong evidence that the reductive metabolism of halothane is similar in the model and man. It is interesting that the ratio of CTF to CDF at 100% oxygen in man is similar to that seen in the model at 14% oxvgen.
Tt should be acknowledged that some differences may be expected in comparing hea !thy unoperated rats to surgical patients with some degree of systemic disease and undergoing a surgical procedure.
The reductive substance BCDF was reported by Sharp et al. (1978) to be due to reaction of halothane with hot soda lime and this has been confirmed in the present study. However, BCDF was not seen in the breath of man or rats when halothane was administered in the absence of soda lime. It seems likely, however, that some BCDF is formed in human liver, but is rapidly bound to liver macromolecules to form the N-acetyl cysteine conjugate of BCDF, which Cohen et al. (1975) detected in the urine. The latter urinary metabolite is the only one not detected to date in the urine of the animal model, and its detection is necessary to complete the validation. The presence in the breath of man of CTF and CDF and also detection in urine of N-acetyl cysteine conjugate of BCDF indicates that reactive intermediates must be formed as either reactive carbanions or free radicals (Figu re 8). The present study indicates t:hat the amounts of these reactive substances increase considerably under conditions of hypoxia and enzyme induction.
HALOTHANE HEPATOTOXICITY
Considerable
insight into halothane's potential hepatotoxicity has been provided by recent in vitro and in vivo animal data: hepatotoxicity in both situations is fostered by non-oxygen dependent biotransformation. This is based on three types of data: (1) reductive products of halothane biotransformation, (2) binding of halothane to cytochrome P-450 (Brown and Sipes 1977) , (3) covalent binding of halothane metabolites to liver proteins and phospholipids , are all enhanced in an hypoxic atmosphere. The latter suggests that reductive metabolites of halothane are far more reactive than the oxidative metabolites. As shown in the present study, small amounts of reductive metabolites are present following normoxic halothane anaesthesia in man and in the model. It should be noted however that the mean concentrations of reductive metabolites after halothane anaesthesia in the study of Sharp et al. were approximately 1/5 of those reported in the present study during anaesthesia. Hypoxia and enzyme induction plus halothane anaesthesia in the model results in a considerable increase in volatile reductive metabolites. Brown and Sipes (1977) noted in a review that severe centrilobular necrosis could be produced in rats given halothane with 14% oxygen and pretreated with phenobarbitone. It is of interest that the centrilobular area of the liver usually has the lowest oxygen concentration, and is most susceptible to hypoxia. In the present study there was a four-to eightfold increase in volatile reductive metabolites in the presence of enzyme induction and hypoxia; this was associated with centrilobular hepatic necrosis. This was an organ specific effect since kidney morphology was normal and the animals' general homeostasis was maintained close to normal as evidenced by normal pH. Halothane anaesthesia in the presence of either hypoxia or enzyme induction alone did not result in hepatic necrosis, indicating that large amounts of reactive intermediates are required to produce direct cellular injury.
A detailed examination of the damage to the hepatocyte caused by the administration 1 % halothane in 14% oxygen to phenobarbitone pretreated rats will be the subject of a separate communication. However, there are similarities between the damage reported in the present communication and that reported for halothane hepatitis in man (Wills and Walton 1978, Uzunalimoglu et al. 1970) : for example, swollen hepatocytes with cytoplasmic pallor are seen with marked dilatation of the rough endoplasmic reticulum and large lipid droplets; damage is confined to the centrilobular region of the liver. The similarity of the morphological findings in the model to those seen in man provide further evidence that the mechanism of toxicity demonstrated in the model has relevance to man.
A previous model (Reynolds and Moslen 1977) was based on pretreatment with polychlorobiphenyls (PCB's), which per se appear to favour reductive metabolism; hepatic necrosis followed halothane in 99% oxygen in this model, however, PCB's themselves produce moderate liver changes invalidating the model (Brown and Sipes 1977) . The present study reports an animal model with the same route of halothane metabolism as man; the hepatic lesion is also the same as that reported in man -centrilobular necrosis. Similar to man there was also a cellular infiltrate composed of lymphocytes and polymorphs. However, the small number of cells would be in keeping with scavenging of the cellular debris. It may also indicate that covalent binding of reductive metabolites to macromolecules has elicited an immunological response. It remains to be seen if this provides an indirect mechanism for the toxicity of reductive metabolites or is merely an associated finding. The presence of an immune response in man is supported by recent findings (Price et al. 1977 ) of a positive "leucocyte migration inhibition factor test" in some patients with hepatotoxicity following Allaesthesia alld Illtells;"e Care, Vol. VIl. No, 1, February, 1979 repeated halothane anaesthesia. Alternatively, increased biotransformation due to enzyme induction may be the mechanism for this reported increase in incidence of hepatic necrosis following repeat exposure to halothane, and, accumulation of toxic metabolites in the liver may also play a part (Stoyka and Havasi 1977 ) . As yet direct evidence is not available for an increased risk of hepatotoxicity resulting from metabolic changes associated with repeat exposure to halothane. It remains possible that a small percentage of patients are "allergic" to one of the halothane metabolites and this may be an alternative mechanism of toxicity to the one described in this paper.
Data presented in this paper support a mechanism for toxicity based upon metabolic activation. It is clear that realisation of this potential toxicity requires either environmental or genetic influences superimposed upon metabolism. The studies reported here have demonstrated that the environmental factors hypoxia and enzyme induction provide a POSSIBLE mechanism for direct hepatotoxicity in man. This mechanism shows promise for delineating appropriate preventive and therapeutic measures. The alternative genetic influence is totally unpredictable and implies that some individuals may have predominantly reductive metabolism, even at normoxia. Although several reports have been made verbally (Cohen, E. N., personal communication) that some Mexican-Americans manifest this abnormality; there is as yet no firm documentation.
HEPATOTOXICITY OF OTHER ANAESTHETICS
Previous studies reporting a significant hepatotoxicity of anaesthetic agents are those relating to fluoroxene and to chloroform. Chloroform's hepatotoxicity (as well as its nephrotoxicity) appears to be due to biotransformation since enzyme induction increases toxicity (Scholler 1970) , and parenohymal damage is not detectable until four hours after chloroform anaesthesia. Although the toxic metabolite has not been identified, glutathione is able to exert a protective effect, presumably by mopping up a postulated free radical (CCl i) formed by the cytochrome P-450 oxidative pathway. A dose-response relationship for chloroform hepatotoxicity has not been demonstrated to date, and would be of use in comparing hepatic toxicity of equipotent doses of the other anaesthetic agents. To date evidence available indicates that glutathione does NOT exert a protective effect in halothane hepatotoxicity so that the mechanism may be somewhat different to that of chloroform.
Fluoroxene is metabolized to trifluoroethanol in animals and in the presence of enzyme induction hepatic necrosis occurs (J ohnston et al. 1973) . In man fluoroxene is metabolized to trifluoroacetic acid, and hepatotoxicity was thought not to occur, although one case was reported in a patient taking phenobarbitone and diphenylhydantoin (Reynolds and Moslen 1977) . Methoxyflurane and enflurane are both capable of nephrotoxicity due to their metabolism to inorganic fluoride, in the animal model , Cousins et al. 1978 and also in man . However, although case reports of hepatic toxicity of both drugs have appeared in the literature there is no firm evidence in man or in the model for suoh an association. Methoxyflurane is felt by some to cause "cross-sensitization" with halothane since hepatic injury in some cases resembled "halothane hepatitis" (Joshi and Conn 1974) ; no direct evidence is available for this relationship.
CONCLUSION
In conclusion, there now seems little doubt that at least one important mechanism for the hepatotoxicity of halothane relates to its reductive metabolism. However, in order for hepatic necrosis to occur, it is necessary to produce a large quantitative change in metabolism by enzyme induction and moderate hypoxia. This study has presented evidence that an animal model for halothane hepatotoxicity in man is at hand. This may permit delineation of important preventive measures to avoid the rare, but tragic occurrence of massive hepatic necrosis following halothane anaesthesia. making the glass assembly for the collection of volatile metabolites from rats. Excellent technical assistance was also provided by Mr. Kent Parkin.
